Overview
Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
Making a Difference in Survival: Integrating New Therapies for Triple-Negative Breast Cancer
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role.
This activity is intended for medical oncologists, surgical oncologists, oncology nurses, and other healthcare providers who care for patients with TNBC.
TNBC is an aggressive disease that disproportionately affects African American women in the United States. Treatment options are limited for TNBC compared with other types of breast cancer, but new therapies hold promise for improved patient outcomes. This activity aims to help the multidisciplinary TNBC team with practical strategies to integrate evidence-based alternative treatment options such as TROP2 targeted ADCs into practice.
Upon completion of this activity, participants will be able to:
-Discuss new targeted treatment approaches in the setting of TNBC
-Discuss the role of ADC therapies and TROP2 for triple-negative breast cancer
Sponsored by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an independent educational grant from Gilead Sciences, Inc.
Sarah Donahue, MPH, NP, AOCNP
Breast Oncology Nurse Practitioner
Breast Cancer Center
UCSF Medical Center
San Francisco, CA
Breast Oncology Nurse Practitioner
Breast Cancer Center
UCSF Medical Center
San Francisco, CA
Amir Momeni-Boroujeni, MD
Assistant Attending Pathologist L1
Memorial Sloan Kettering Cancer Center
New York, NY
Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, IL
The University of Chicago Pritzker School of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Sarah Donahue, MPH, NP, AOCNP (Faculty)
Advisory Board: Sanofi Genzyme
Honorarium Recipient: Pfizer
Rita Nanda, MD (Faculty)
Advisory Boards: Aduro, Clovis, Daiichi Sankyo, Fujifilm, Genentech/Roche, Immunomedics, Macrogenics, Merk, Pfizer, Seattle Genetics, GI Therapeutics, AstraZeneca, Celegene, Corcept Therapeutics, OBI Pharma, Odonate Therapeutics
Amir Momeni-Boroujeni, MD (Faculty) has no financial relationships to report.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational datopotamab deruxtecan, ladiratuzumab vedotin, trastuzumab deruxtecan
The University of Chicago Pritzker School of Medicine and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago Pritzker School of Medicine and ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Update as of August 5, 2022: Fam-trastuzumab-deruxtecan-nxki is now approved to treat patients with unresectable or metastatic HER2-low breast cancer.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Ty Jackson at tjackson@achlcme.org.
The University of Chicago Pritzker School of Medicine Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professional CreditNurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
